Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 05/11/2020, Revision: 5, Status: Authorised
The most common side effects with Calquence (which may affect more than 1 in 5 people) are infections, headache, diarrhoea, bruising, muscle pain, nausea (feeling sick), tiredness, cough and rash. When used in combination with other cancer medicines, joint pain, dizziness and constipation were also very common.
The most common serious reactions with Calquence (which may affect more than 1 in 20 people) were infections and low white and red blood cell counts (leucopenia, neutropenia, and anaemia).
For the full list of side effects and restrictions with Calquence, see the package leaflet.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
